TheAnswerPage

JUNE 21, 2022

There is a high strength of evidence for the efficacy of cannabinoid-based medicines for the treatment of intractable epilepsy, multiple sclerosis and cancer-related nausea. Which of these 3 conditions has the greatest relative number of patients using cannabinoid -based medicines to treat the condition? Schlag, A.K.,

Epilepsy 52

Epilepsy Cannabinoids Medicine Conditions 52

TheAnswerPage

JULY 18, 2022

Do patients report more side effects from cannabidiol (CBD)-rich extract therapy or from purified CBD therapy? Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis Front. Pamplona F, da Silva L and Coan A. 12 September 2018.

Epilepsy 52

Epilepsy Therapy Extraction Treatment 52

TheAnswerPage

AUGUST 8, 2022

Some patients apply CBD topically. Currently, CBD-containing gels are being evaluated for the treatment of several pediatric disorders, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Does CBD easily penetrate the skin? See the Answer.

Epilepsy 59

Epilepsy Topical Treatment CBD 59

MMJ Recs

AUGUST 29, 2022

Missouri dispensaries are now selling high-quality, locally produced marijuana products to hundreds of thousands of Missouri MMJ patients. Missouri medical marijuana patients get to shop (as well as browse and learn) at some of the best MMJ dispensaries in the country. So what are the best dispensaries in MO?

Dispensary 52

Dispensary Patients Treatment Education 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: [link] Accessed October 17, 2022. May 26, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

TheAnswerPage

MAY 9, 2022

Some patients apply CBD topically. Currently, CBD-containing gels are being evaluated for the treatment of several pediatric disorders, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Does CBD easily penetrate the skin? See the Answer.

Epilepsy 59

Epilepsy Topical Treatment CBD 59

TheAnswerPage

DECEMBER 31, 2021

There is a high strength of evidence for the efficacy of cannabinoid-based medicines for the treatment of intractable epilepsy, multiple sclerosis and cancer-related nausea. Which of these 3 conditions has the greatest relative number of patients using cannabinoid -based medicines to treat the condition? Schlag, A.K.,

Epilepsy 52

Epilepsy Cannabinoids Medicine Conditions 52

TheAnswerPage

JUNE 29, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

JANUARY 9, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

The Cannigma

JULY 12, 2022

Roll out of the program has been slow, and as of June 2022, there were still no doctors certified to issue prescriptions, no licensed dispensaries, and no legal farming of cannabis products. Unlike other states, Alabama requires doctors to document a failure of conventional medical treatment before issuing a medical cannabis prescription.

Legalization 122

Legalization Chronic Pain Programs Treatment 122

The Cannigma

JUNE 25, 2022

Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Medical patients are also responsible for 100% of the cost of medication, making it cost-prohibitive to many. Medical cannabis has been legal in Poland since 2017. Is CBD legal in Poland?

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

The Cannigma

JULY 5, 2022

The program was legalized in 2015 and patients with qualifying conditions can get a prescription for up to 20oz of low THC oil, capsules, patches, or lotion. But it is a medical program in name only, because as of June 2022 there were no licensed dispensaries in Georgia. In 2015, Georgia legalized possession of up 20 fl.

Law 96

Law Decriminalization Programs Patients 96

Cannabis Law Report

AUGUST 31, 2021

Alixen™ 30 will target indications such as anxiety, insomnia, Parkinson’s Disease, and depression, while Alixen™ 100 will be used in the treatment of epilepsy.

Chronic Pain 105

Chronic Pain Epilepsy THC Patients 105

MMJ Recs

DECEMBER 15, 2021

These states recognize MMJ cards from other states and allow patients with out-of-state cards to purchase medical marijuana legally in local dispensaries. This means that MMJ patients from other states will be able to purchase recreational marijuana in New York from late 2022. Does New York Accept Out-of-State MMJ Cards?

Chronic Pain 98

Chronic Pain Dispensary Recreational Patients 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

PrestoDoctor

FEBRUARY 13, 2023

Learn about how to become a medical marijuana patient so you can get access to medical cannabis in Missouri. Qualifying patients may be certified by an MD, DO, or a nurse practitioner. The application fee for an MMJ is $25 per patient or primary caregiver. Requirements for a Medical Marijuana Card in Missouri?

Marijuana 52

Marijuana Conditions Patients Cultivation 52

Cannabis Law Report

FEBRUARY 19, 2022

The AMCC anticipates that applicants may submit licenses to grow and/or manufacture medical cannabis on September 1, 2022. Under current law , the Florida Department of Health (FDOH) is responsible for overseeing the medical cannabis program, including issuing licenses to medical cannabis treatment centers.

Legalization 97

Legalization Seed-To-Sale Programs Dispensary 97

Cannabis Law Report

SEPTEMBER 1, 2022

AUSTIN, Texas, August 31, 2022 –( BUSINESS WIRE )–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). of cannabis patients. According to a 2021 Harm Reduction Journal study , 38.1%

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

JUNE 1, 2022

2 June 2022. Millions of consumers and patients around the world will be heartened by the results of the latest study on cannabis and driving. These amounts represent frequently consumed dosages: up to 150mg/day over the counter; and up to 1500mg/day for conditions such as epilepsy, pain, sleep disorders and anxiety.

CBD 52

CBD Blood Pressure Sleep Concentrates 52

MMJ Recs

FEBRUARY 9, 2022

So that more people can gain access to the treatment, the Louisiana MMJ program continues to expand, with more qualifying conditions added to the list as well as more cannabis included under the MMJ umbrella. It states that patients must receive a recommendation from their doctor and have a condition that qualifies.

Marijuana 52

Marijuana Conditions Access Chronic Pain 52

MMJ Recs

OCTOBER 10, 2021

Large numbers of OK residents are benefitting from medical marijuana treatment, and MMJ is also bringing massive economic benefits to the Sooner State. The MMJ program in Oklahoma is liberal and patient-friendly. Oklahoma MMJ Is A Very Effective Treatment For Many Medical Conditions. MMJ Has Lessened Oklahoma’s Opioid Problems.

Dispensary 52

Dispensary Treatment Chronic Pain Conditions 52

Cannabis Law Report

AUGUST 31, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. of cannabis patients. According to a 2021 Harm Reduction Journal study , 38.1%

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax initially focused strictly on pain product candidates.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

MMJ Recs

JULY 25, 2022

How do I get a medical card in Michigan in 2022? Image by albertoadan on Pixabay : How do I get a medical card in Michigan in 2022? The application fee for a Michigan MMJ card is $40, by a check or money order payable to State Of Michigan-MMMP. How Can I Get A Medical Marijuana Card In Michigan?

Chronic Pain 52

Chronic Pain Marijuana Recreational Dispensary 52

MMJ Recs

SEPTEMBER 15, 2021

Thankfully for MMJ patients in the Show-Me State, the answer to this much-asked question is a resounding yes! It is hoped that a vote will happen in 2022. They also provide education and information to patients about MMJ treatment and new products. Does Missouri have recreational MMJ dispensaries? Read on to find out.

Recreational 52

Recreational Dispensary Conditions Access 52

Veriheal

MARCH 23, 2023

Aside from Japan legalizing medical marijuana and forging a legal pathway that enables patients to use drugs made from cannabis plants, the amended legal law also seeks to criminalize the use of marijuana. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

NewsMunchies

SEPTEMBER 5, 2018

A new marijuana-derived drug to treat rare forms of severe epilepsy in children will cost about $32,500 per patient, per year. patients this fall, following rescheduling, which is expected to occur within 90 days of FDA approval,” said GW Pharmaceuticals’ CEO Justin Gover. “We is expected to soar to $22 billion in 2022.

Supply Chain 40

Supply Chain DEA Pharmaceutical Chronic Pain 40

SpeedWeed

MAY 20, 2021

WDSU said that the outcome “likely dooms the prospect of legalized marijuana in the state this year,” and “also likely dooms the approval of legalized weed next year, since tax bills cannot be brought up in 2022, as it is not a fiscal session then.”.

Recreational 52

Recreational Legislation Programs Epilepsy 52

Cannabis Law Report

SEPTEMBER 20, 2021

Founded in 2016, Calyx is headquartered in Massachusetts and plans to be vertically integrated in three states by the end of 2022. “We As of August 31, 2021, there were over 177,000 patient applications and 5,800 caregiver applications in the state. million rentable square feet (including approximately 2.6

Cultivation 52

Cultivation Dispensary Patients Epilepsy 52

Cannabis Law Report

MARCH 6, 2020

” In 2018, Europe was responsible for 23.2% of the world’s pharmaceutical sales with the size of the market in the EU-5 ( United Kingdom , Germany , Spain , France , and Italy ) set to grow by 25% between 2017 and 2022. KLS-13019 has not been reviewed or approved for patient use by the U.S. About Kannalife, Inc.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Freedom Leaf

OCTOBER 15, 2018

On the basis of their review, the agency approved Epidiolex for use in treating rare forms of childhood epilepsy (Lennox-Gastaut syndrome and Dravet syndrome). billion by 2022. billion by 2022. A month later, on May 16, the Department of Health and Human Services approved the FDA’s Epidiolex recommendation. will top $1.9

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

JANUARY 5, 2022

The patent will be issued on January 11, 2022. This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. Silver Spike Acquisition Corp. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

OCTOBER 20, 2019

It is also the first FDA approved drug for the treatment of patients with Dravet syndrome. Big Pharma companies want botanical marijuana to remain illegal because it is financially beneficial to them, not because synthetic marijuana is decidedly better for patients.” billion by 2022 from $3.1 as a Schedule II substance.

Marijuana 45

Marijuana Pharmaceutical Chronic Pain Research and Development 45

Cannabis Law Report

MAY 19, 2022

FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. CBD oil is an effective natural treatment for OCD.”. “If FDA states it has serious safety concerns with delta-8 THC. FDA Warning Letters. and reduce anxiety and nervousness.”.

THC 52

THC CBD Food Pets 52